公开(公告)号：US20250042857A1

公开(公告)日：2025-02-06

申请号：US18695940

申请日：2022-09-28

Applicant: HAIHE BIOPHARMA CO., LTD.

Inventor： Dongsheng LI ,  Shanyun GAO ,  Cailu LIU ,  Yalei CAI ,  Maozhi YANG ,  Wangyang TU ,  Bing YU ,  Qing XIE ,  Yixiang ZHANG ,  Leping LI

IPC: C07D215/44 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4706 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D409/12 ,  C07D471/04 ,  C07D519/00

Abstract: The present invention relates to an SOS1 inhibitor with a pyrido-fused-six-membered ring structure, a preparation method therefor, and use thereof. The SOS1 inhibitor has the structural formula shown in formula (I) and an inhibitory activity on SOS1, and can be used to treat head and neck cancer, lung cancer, a mediastinal tumor, a gastrointestinal tumor, prostate cancer, testicular cancer, a gynecological tumor, breast cancer, renal and bladder cancer, an endocrine tumor, soft tissue sarcoma, osteosarcoma, rhabdomyosarcoma, mesothelioma, skin cancer, a peripheral nerve tumor, a central nervous system tumor, lymphoma, leukemia, Noonan syndrome, cardio-facio-cutaneous syndrome, and hereditary gingival fibromatosis and a related syndrome thereof.